MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585426 | Name: Ciclazindol (free base)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ciclazindol (free base) is a noradrenaline uptake inhibitor.

Chemical Structure

Ciclazindol (free base)
Ciclazindol (free base)
CAS#37751-39-6 (free base)

Theoretical Analysis

MedKoo Cat#: 585426

Name: Ciclazindol (free base)

CAS#: 37751-39-6 (free base)

Chemical Formula: C17H15ClN2O

Exact Mass: 298.0873

Molecular Weight: 298.77

Elemental Analysis: C, 68.34; H, 5.06; Cl, 11.87; N, 9.38; O, 5.35

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
37751-39-6 (free base) 37647-67-9 (HCl)
Synonym
Ciclazindol; WY 23,409; WY-23,409; WY23,409
IUPAC/Chemical Name
10-(3-chlorophenyl)-3,4-dihydro-2H-pyrimido[1,2-a]indol-10-ol
InChi Key
VKQDZNZTPGLGFD-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H15ClN2O/c18-13-6-3-5-12(11-13)17(21)14-7-1-2-8-15(14)20-10-4-9-19-16(17)20/h1-3,5-8,11,21H,4,9-10H2
SMILES Code
OC1(C2=CC=CC(Cl)=C2)C3=NCCCN3C4=C1C=CC=C4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 298.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zygmunt PM, Edwards G, Weston AH, Larsson B, Högestätt ED. Involvement of voltage-dependent potassium channels in the EDHF-mediated relaxation of rat hepatic artery. Br J Pharmacol. 1997 May;121(1):141-9. PubMed PMID: 9146898; PubMed Central PMCID: PMC1564657. 2: Kerr FA, Szabadi E. Comparison of the effects of chronic administration of ciclazindol and desipramine on pupillary responses to tyramine, methoxamine and pilocarpine in healthy volunteers. Br J Clin Pharmacol. 1985 May;19(5):639-47. PubMed PMID: 4005103; PubMed Central PMCID: PMC1463841. 3: Harvey J, Ashford ML. Diazoxide- and leptin-activated K(ATP) currents exhibit differential sensitivity to englitazone and ciclazindol in the rat CRI-G1 insulin-secreting cell line. Br J Pharmacol. 1998 Aug;124(7):1557-65. PubMed PMID: 9723971; PubMed Central PMCID: PMC1565548. 4: McKay NG, Kinsella JM, Campbell CM, Ashford ML. Sensitivity of Kir6.2-SUR1 currents, in the absence and presence of sodium azide, to the K(ATP) channel inhibitors, ciclazindol and englitazone. Br J Pharmacol. 2000 Jun;130(4):857-66. PubMed PMID: 10864893; PubMed Central PMCID: PMC1572145. 5: Waterfall JF, Smith MA, Gaston WH, Maher J, Warburton G. Cardiovascular and autonomic actions of ciclazindol and tricyclic antidepressants. Arch Int Pharmacodyn Ther. 1979 Jul;240(1):116-36. PubMed PMID: 507990. 6: Noack T, Edwards G, Deitmer P, Greengrass P, Morita T, Andersson PO, Criddle D, Wyllie MG, Weston AH. The involvement of potassium channels in the action of ciclazindol in rat portal vein. Br J Pharmacol. 1992 May;106(1):17-24. PubMed PMID: 1504725; PubMed Central PMCID: PMC1907450. 7: Oh VM, Ehsanullah RS, Leighton M, Kirby MJ. Influence of ciclazindol on monoamine uptake and CNS function in normal subjects. Psychopharmacology (Berl). 1979 Jan 31;60(2):177-81. PubMed PMID: 106428. 8: Rothwell NJ, Stock MJ, Wyllie MG. Sympathetic mechanisms in diet-induced thermogenesis: modification by ciclazindol and anorectic drugs. Br J Pharmacol. 1981 Nov;74(3):539-46. PubMed PMID: 6271318; PubMed Central PMCID: PMC2071762. 9: Levine S. A controlled comparative trial of a new antidepressant, ciclazindol. J Int Med Res. 1979;7(1):1-6. PubMed PMID: 369921. 10: Lee K, Khan RN, Rowe IC, Ozanne SE, Hall AC, Papadakis E, Hales CN, Ashford ML. Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells. Mol Pharmacol. 1996 Apr;49(4):715-20. PubMed PMID: 8609901. 11: Wheatley D. A new weight-reducing drug with novel properties. Postgrad Med J. 1982 May;58(679):279-81. PubMed PMID: 7050949; PubMed Central PMCID: PMC2426414. 12: Kirby MJ, Turner P. Ciclazindol and mazindol on glucose uptake into human isolated skeletal muscle: no interaction of mazindol with methysergide. Br J Clin Pharmacol. 1977 Aug;4(4):459-61. PubMed PMID: 901738; PubMed Central PMCID: PMC1429039. 13: Lang SS, Danforth E Jr, Lien EL. Anorectic drugs which stimulate thermogenesis. Life Sci. 1983 Sep 26;33(13):1269-75. PubMed PMID: 6888178. 14: Green ME, Edwards G, Kirkup AJ, Miller M, Weston AH. Pharmacological characterization of the inwardly-rectifying current in the smooth muscle cells of the rat bladder. Br J Pharmacol. 1996 Dec;119(8):1509-18. PubMed PMID: 8982495; PubMed Central PMCID: PMC1915784. 15: Petersson J, Zygmunt PM, Högestätt ED. Characterization of the potassium channels involved in EDHF-mediated relaxation in cerebral arteries. Br J Pharmacol. 1997 Apr;120(7):1344-50. PubMed PMID: 9105711; PubMed Central PMCID: PMC1564595. 16: Lean ME, Borthwick LJ. Ciclazindol: an oral agent with weight reducing properties and hypoglycaemic activity. Eur J Clin Pharmacol. 1983;25(1):41-5. PubMed PMID: 6352281. 17: White R, Hiley CR. A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br J Pharmacol. 1997 Dec;122(8):1573-84. PubMed PMID: 9422801; PubMed Central PMCID: PMC1565105. 18: Rothwell NJ, Stock MJ, Wyllie MG. Influence of chronic administration of ciclazindol on energy balance and brown adipose tissue in adult 'cafeteria'-fed rats. J Auton Pharmacol. 1983 Jun;3(2):73-8. PubMed PMID: 6309850. 19: Wyllie MG, Fletcher A, Rothwell NJ, Stock MJ. Thermogenic properties of ciclazindol and mazindol in rodents. Int J Obes. 1984;8 Suppl 1:85-92. PubMed PMID: 6534897. 20: Swaisland AJ, Franklin RA, Southgate PJ, Coleman AJ. The pharmacokinetics of ciclazindol (Wy 23409) in human volunteers. Br J Clin Pharmacol. 1977 Feb;4(1):61-5. PubMed PMID: 843425; PubMed Central PMCID: PMC1428987.

View History

Ciclopirox Olamine

Ciclopirox Olamine

Featured